本帖最后由 老马 于 2012-1-13 21:20 编辑 $ V; S$ S% F( ]7 o* D 
 
/ G( M: _" b1 [' G爱必妥和阿瓦斯丁的比较 
8 c2 D3 L( o. L: d- M
 
9 }, h& _5 i" | 
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/ 
3 m- I9 h. r/ B/ z3 j/ Q
 
 
( r1 i' E$ b5 a8 E1 v
 
 
# A' X. X) @6 K# e* }6 `. T: }# l, phttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/7 N& W* h9 x0 Z5 j% U. C3 [6 y 
==================================================" v5 z! B) P, r) i 
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% F! ~: Q$ ]+ l4 v/ F4 @ 
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 
. N6 k  }9 m6 r. lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 
6 c. |; m; n$ G# i8 ~; f
 
 |